Chester County News and Community Website
PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) has revealed significant progress in its pipeline and operations, underscoring its focus on advancing rese-cel, a cell therapy candidate for autoimmune diseases. …
Cabaletta Bio Advances Autoimmune Therapy, Sets Strategic Goals for 2025 Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) recently presented encouraging clinical data for its investigational therapy, CABA-201, at the American College of Rheumatology (ACR) Convergence 2024 in Washington, D.C. …
Cabaletta Bio Unveils Promising Data on CABA-201 at ACR Convergence 2024 Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) has released its financial results for the third quarter of 2024, alongside updates on its clinical trial programs. A key highlight includes …
Cabaletta Bio Reports Q3 2024 Financial Results and Clinical Trial Advancements Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) announced its financial results for the second quarter ended June 30, 2024, along with key business updates.
Cabaletta Bio Reports Q2 2024 Financial Results and Provides Business Update Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) has released positive preliminary clinical data from its Phase 1/2 trials of CABA-201, a new potential treatment option for patients with autoimmune …
Cabaletta Bio Reports Promising Early Results for New Autoimmune Disease Treatment Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) this week unveiled promising updates on its clinical trials and financial standing for the first quarter ending March 31, 2024. The company’s …
Cabaletta Bio Reports Promising Advances in Autoimmune Disease Trials, Looks to Future Innovations Read More